Momentum is mounting in the Senate to reform a prescription drug pricing program whose rapid growth, lawmakers contend, has led to higher costs for patients and taxpayers.
The Senate Committee on Health, Education, Labor and Pensions held a hearing Thursday on the 340B drug pricing program, which allows certain healthcare facilities that serve low-income patients to purchase outpatient drugs at a discounted rate.
“Anyone who says that 340B is cost neutral to taxpayers is not paying attention,” Committee Chair Sen. Bill Cassidy, R-La., said.
Read more at Newsmax© 2025 Newsmax. All rights reserved.